scholarly journals THU0652-HPR ONLINE EDUCATION YIELDS SIGNIFICANT GAINS IN RHEUMATOLOGISTS’ KNOWLEDGE OF BIOLOGICS AND BIOSIMILARS BUT A SUBSTANTIAL GAP REMAINS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 570.2-571
Author(s):  
A. Stan ◽  
E. Bell ◽  
P. Schoonheim ◽  
E. Mysler
Keyword(s):  
Online Education ◽  
Statistical Significance ◽  
Treatment Options ◽  
Educational Activity ◽  
Round Table Discussion ◽  
Knowledge Gain ◽  
Regulatory Requirements ◽  
Research Support ◽  
Significance Level ◽  
Post Assessment

Background:Biologics are complex proteins which have revolutionized the treatment of many serious diseases. Due to their complexity and manufacturing which involves living organisms, it is not possible to create identical versions of reference biologics, but it is possible to create biosimilar drugs. Biosimilars have the potential to yield high cost savings and expand treatment options to meet the growing demand for biological therapies.Objectives:This study assessed whether the online CME-accredited round-table-discussion titled “Understanding Biologics: from protein to clinical practice” improved physicians’ understanding of the inherent variability of biologics and what similarity means in the context of biologics as well as the analytical assessment of quality that applies to both biologics and biosimilars.Methods:Rheumatologists participated in an online CME activity (www.medscape.org/viewarticle/900121) consisting of a 30-minute video discussion between 4 experts with accompanying slides. Educational effect was assessed using a 4-question repeated pairs, pre-/post-assessment. A chi-square test was used to determine if a statistically significant improvement (P<.05 significance level) existed in the number of pre-/post-test correct responses. Cramer’s V was used to estimate the level of impact of the education. The CME activity launched on 22 Aug 2018, and the data were collected through 9 Oct 2018.Results:A total of 622 rheumatologists participated in the educational activity, and 87 completed the pre- and postassessment. Overall the activity had a signficiant impact (P<.001) on rheumatologists’ understanding of the inherent variability of biologics and the regulatory requirements for approval of a biosimilar. The Cramer’s V value of 0.186 indicates a considerable effect of the education. The average perecentage of correct responses rose from 33% pre-activity to 51% post-activity. A linked learning assessment (individual responses matched pre- and post-education) showed that 25% of learners improved their knowledge and 26% reinforced their knowledge. The change in percentage of correct responses from pre- to post-assessment achieved statistical significance (P<.05) in 2 of the 3 questions presented: (i) understanding the type of studies needed to demonstrate comparability of a biosimilar to an originator (11% at baseline; 45% post activity), (ii) understanding the type of variability considered acceptable for a biologic (46% at baseline; 63% post activity). However, no knowledge gain was observed regarding basic analytic attributes evaluated to ensure batch to batch consistency (37% at baseline; 38% post activity). Almost 45% of rheumatologists gained confidence in their ability to describe the regulatory requirements for approval of a biosimilar.Conclusion:This online CME activity significantly improved rheumatologists’ understanding of the inherent variability of complex biologic medicines and the role of analytical studies in the regulatory approval of biosimilars. However, there is room for further improving physicians’ knowledge, especially of basic analytics of biologics and biosimilars.Acknowledgments:This CME-certified activity was supported by independent funding from Sandoz.Disclosure of Interests:Adriana Stan Grant/research support from: The CME-certified activity was supported by anindependent educational grant from Sandoz., Elaine Bell: None declared, Peter Schoonheim Grant/research support from: This CME-certified activity was supported by independent funding from Sandoz., Eduardo Mysler Grant/research support from: AbbVie, Lilly, Pfizer, Roche, BMS, Sandoz, Amgen, and Janssen., Consultant of: AbbVie, Lilly, Pfizer, Roche, BMS, Sandoz, Amgen, and Janssen.

Optimizing management of glioblastoma: Educational impact on clinicians.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 11026-11026
Author(s):  
Michelle Arielle Worst ◽  
Ann Carothers ◽  
Kinjal Parikh ◽  
Lisa Brauer ◽  
Giuseppe Lombardi ◽  
...  
Keyword(s):  
Clinical Care ◽  
Statistical Significance ◽  
Treatment Options ◽  
Educational Activity ◽  
Molecular Testing ◽  
Chi Square ◽  
Assessment Scores ◽  
Confidence Assessment ◽  
Investigational Agents ◽  
Post Assessment

11026 Background: Glioblastoma multiforme (GBM) is a rare, malignant tumor of the central nervous system (CNS) with poor prognosis. Nearly all patients experience recurrence due to GBM’s heterogeneity and there is currently no standard approach to treatment. Despite having few targeted agents with demonstrated efficacy, molecular testing is utilized due to its value in improving diagnostic accuracy and prognostic stratification. Moreover, recent data has shown an increase in promising data with regards to treating GBM using various mechanisms. Because of the clinical conundrum GBM poses and the lack of available treatment options, clinicians are challenged to stay current with new data and how best to integrate new agents into treatment paradigms. The objective of this study was to assess the changes in oncologists’ and pathologists’ knowledge through participation in education regarding optimal GBM treatment. Methods: The educational activity was a 30-minute online, video discussion segmented into 3 parts with synchronized slides and 2 faculty. Educational effect was assessed with a repeated pairs pre-/post-assessment study with a 3-item, multiple choice, knowledge questionnaire and one confidence assessment question. For all questions, each participant served as his/her own control. Pre- and post-assessment scores were compared to determine the relative changes in the proportion of correct responses. A chi-square test assessed statistical significance at the P < 0.05 level. The activity launched 26th June 2019; data were collected until 19th August 2019. Results: Overall significant improvements were seen after education for oncologists (N = 62, P < .001) and pathologists (N = 67, P < .01). The relative improvement was 67% for oncologists and 45% for pathologists (pre-/post-assessment average correct response rates were 30%/50% and 29%/42%, respectively). Following the activity, 55% of oncologists and 51% of pathologists had a measurable improvement in confidence in their ability to differentiate among late-stage investigational agents for GBM based on mechanism of action. Conclusions: Participation in an online, CME intervention consisting of a series of video discussions, totaling 30-minutes, resulted in statistically significant improvements in knowledge and confidence of oncologists and pathologists, that may lead to improvements in clinical care. As new data and agents emerge, new educational activities are necessary to reinforce knowledge, close persistent gaps, and increase oncologists’ and pathologists’ confidence in this clinical setting.

scholarly journals P569 Online education significantly improved gastroenterologists’ knowledge of management strategies and treatment options for ulcerative colitis

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S528-S528
Author(s):  
E Bell ◽  
M Calle
Keyword(s):  
Ulcerative Colitis ◽  
Online Education ◽  
Drug Targets ◽  
Treatment Options ◽  
Treatment Success ◽  
Management Strategies ◽  
Rapid Evolution ◽  
Continuous Medical Education ◽  
Significance Level ◽  
Average Percentage

Abstract Background Ulcerative colitis (UC) is a challenging condition for gastroenterologists to manage. With the rapid evolution of the treatment landscape and more stringent goals for therapy, many physicians may struggle to stay abreast of current best practice in UC management. We assessed whether online continuous medical education (CME) can improve gastroenterologists’ knowledge of management strategies and treatment options for UC. Methods Gastroenterologists participated in an online CME activity entitled ‘Key Considerations for Treatment Success in Patients With UC’. This was a 45-minute segmented video activity with accompanying slides. Questions were developed to address each of the educational objectives for the activity. Educational effect was assessed using a repeated-pair design, pre-/post-assessment. A Chi-square test of independence determined if a statistically significant improvement (5% significance level, P&lt;.05) existed in the number of correct responses between the pre-test and post-test scores. Cramer’s V estimated the effect size of the education (&lt;.06, modest impact; .06-.15, noticeable impact; .16-.26, considerable impact; &gt;.26, extensive impact). The activity launched on 16 May 2019 with data collection through 11 September 2019. Results A total of 1173 gastroenterologists participated in the activity. Of those, 171 completed both pre- and post-questions, providing a set of linked learner data for analysis. The results showed: • Significant improvement in average percentage of correct responses, rising from 47% at baseline to 77% post-activity (P&lt;.001) and extensive educational impact (Cramer’s V=.260) • The percentage of gastroenterologists (n=171) answering all 3 questions correctly more than tripled, from 13% pre-activity to 41% post-activity • Significant improvements in knowledge of UC pathogenesis, treatment targets according to STRIDE recommendations, and which drug targets IL-12 and IL-23 (P&lt;.001 for all 3 questions) • 38% of gastroenterologists reported increased confidence in selecting an appropriate therapy for a patient with UC Conclusion Online education significantly improved gastroenterologists’ knowledge of management strategies and treatment options in UC which should support them in achieving successful outcomes for their patients. However, there remains a notable gap in knowledge of the STRIDE recommendations and in confidence regarding treatment selection. These results suggest that gastroenterologists would benefit from additional education to reinforce their knowledge of UC management strategies and improve their confidence in translating these principles into clinical practice.

Understanding the expanding armamentarium for GIST: Engaged learning outcomes.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 837-837
Author(s):  
Michelle Arielle Worst ◽  
Emily Sherene Van Laar ◽  
Mindy Tanzola ◽  
Michael C. Heinrich ◽  
Victor Manuel Villalobos
Keyword(s):  
Clinical Care ◽  
Statistical Significance ◽  
Soft Tissue Sarcomas ◽  
Educational Activity ◽  
Chi Square ◽  
Assessment Scores ◽  
Confidence Assessment ◽  
Resistance Patterns ◽  
Chi Square Test ◽  
Post Assessment

837 Background: Gastrointestinal stromal tumors (GIST) are rare soft-tissue sarcomas that harbor specific genomic alterations, making GIST an ideal model for targeted therapy. Common oncogenic drivers include mutations in the KIT and PDGFR tyrosine kinase. Due to varying resistance patterns to existing TKIs, clinicians are challenged to stay current with new data and how best to integrate new agents into treatment paradigms. The objective of this study was to assess the changes in oncologists’ and gastroenterologists’ knowledge, competence, and confidence through participation in education regarding optimal GIST treatment. Methods: The educational activity consisted of a 30-minute online, 2 faculty, video discussion with synchronized slides. Educational effect was assessed with a repeated pairs pre-/post-assessment study with a 3-item, multiple choice, knowledge/competence questionnaire and one confidence assessment question. For all questions, each participant served as his/her own control. Pre- and post-assessment scores were compared to determine the relative changes in the proportion of correct responses. A chi-square test assessed statistical significance at the P < 0.05 level. The activity launched 25th June 2019; data were collected until 19th August 2019. Results: Overall significant improvements were seen after education for oncologists (N=52, P < 0.001) and gastroenterologists (N=127, P < 0.01). The relative improvement was 79% for oncologists and 44% for gastroenterologists (pre-/post-assessment average correct response rates were 24%/43% and 23%/33%, respectively). Following the activity, 44% of oncologists and 37% of gastroenterologists were more confident in their ability to select appropriate therapy for patients with metastatic GIST. Conclusions: Participation in an online, 30-minute video discussion CME intervention resulted in statistically significant improvements in knowledge, competence, and confidence of oncologists and gastroenterologists, that may lead to improvements in clinical care. As new data and agents emerge, new educational activities are necessary to reinforce knowledge, close persistent gaps, and increase oncologists’ confidence in this clinical setting.

scholarly journals NCOG-13. THE IMPACT OF CME ON THE KNOWLEDGE OF NEUROFIBROMATOSIS TYPE 1-RELATED TUMORS

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii132-ii132
Author(s):  
Michelle Worst ◽  
Kinjal Parikh ◽  
Rich Caracio ◽  
Sara Fagerlie
Keyword(s):  
Neurofibromatosis Type 1 ◽  
Wide Spectrum ◽  
Clinical Care ◽  
Statistical Significance ◽  
Multidisciplinary Treatment ◽  
Neurofibromatosis Type ◽  
Educational Activity ◽  
The Impact ◽  
Post Assessment

Abstract BACKGROUND Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic condition characterized by a wide spectrum of clinical findings. Patients with NF1 develop benign and malignant tumors along the nerves of the skin, brain, and other body parts. Due to the unique presentation of each patient, clinicians are challenged to stay current with emerging data and how best to integrate new agents into multidisciplinary treatment paradigms. The objective of this study was to assess changes in neurologists’ and pediatricians’ knowledge and confidence through participation in education regarding NF1 treatment. METHODS The educational activity consisted of a 30-minute online enduring, 1 faculty, chapterized summary of a live symposium. Educational effect was assessed with a repeated pairs pre-/post-assessment study with a 3-item, multiple choice, knowledge questionnaire and one confidence assessment question. For all questions, each participant served as his/her own control. Pre- and post-assessment scores were compared to determine relative changes in the proportion of correct responses. A chi-square test assessed statistical significance at the P &lt; 0.05 level. The activity launched 23rd December 2019; data were collected until 2nd April 2020. RESULTS Overall, statistically significant improvements were seen after education for neurologists (N=171, P &lt; 0.05) and pediatricians (N=260, P &lt; 0.01). The relative improvement in correct answers was 26% for neurologists and 48% for pediatricians (percent of total correct responses pre-/post-assessment were 27%/34% and 23%/34%, respectively). Following the activity, 16% of neurologists and 22% of pediatricians had a measurable increase in confidence regarding their understanding of multidisciplinary management of NF1. CONCLUSIONS Participation in an online, 30-minute enduring CME intervention resulted in statistically significant improvements in knowledge and confidence of neurologists and pediatricians, that result in improvements in clinical care. Continued educational activities are paramount to address residual gaps and further increase clinicians’ confidence in this clinical setting.

scholarly journals POS1449 SEGMENTED SHORT-FORMAT ONLINE EDUCATION SIGNIFICANTLY INCREASES PREDICTION, PROGNOSIS, AND MANAGEMENT OF FIBROSING INTERSTITIAL LUNG DISEASE ASSOCIATED WITH CONNECTIVE TISSUE DISEASE

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1008.1-1009
Author(s):  
C. Rohani-Montez ◽  
M. Calle ◽  
C. Allen ◽  
T. Maher ◽  
V. Smith ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Connective Tissue ◽  
Online Education ◽  
Lung Disease ◽  
Disease Progression ◽  
Correct Response ◽  
Response Rate ◽  
Research Support ◽  
Post Assessment ◽  
Correct Response Rate

Background:Identifying fibrosing interstitial lung disease (ILD) at the earliest opportunity remains one of the most urgent challenges for the effective management of this potentially rapidly progressive and burdensome condition, which is frequently associated with several connective tissue diseases (CTDs). However, knowledge on how to identify early hallmarks and predictors of fibrosing ILD, as well as knowing which steps to take next is frequently lacking in clinical practice.Objectives:This study was conducted to determine whether online independent medical education could improve rheumatologists’ and pulmonologists’ knowledge and competence in identifying and managing progressive fibrosing ILDs earlier in the disease course.Methods:Rheumatologists and pulmonologists participated in five ~10-min presentations about the early identification of fibrosing ILD in patients with or without CTDs and completed all pre- and post-questions.1 The effects of the education on knowledge and competence were assessed using a 3-question, repeated pairs, pre-assessment/post-assessment study design. For all questions combined, the chi-square test assessed differences from pre- to post-assessment. P values <.05 are statistically significant. The activity launched on October 9, 2020, and data were collected through December 18, 2020.Results:Overall significant improvements were seen after participation for both rheumatologists (average correct response rate of 28% at pre-assessment vs 74% at post-assessment; P<.001, representing a 165% relative percentage change [RPC]; N=39), and pulmonologists (average correct response rate of 39% at pre-assessment vs 67% at post-assessment; P<.001, representing a 72% RPC; N=102). Specifically, significant improvements were observed in clinicians’ knowledge of predictors of fibrosing ILD in patients with CTD, as well as competence in selecting the right HRCT parameters to assess prognosis and select a treatment approach to reduce the risk of disease progression (Figure 1).Figure 1.After participating in the activity, 59% of rheumatologists and 50% of pulmonologists had measurable improved confidence related to identifying early disease progression in patients with progressive fibrosing ILDs.Given the very low rates of correct responses at baseline regarding predictors of fibrosing ILD and assessing prognosis, it will be important to continue to reinforce these learnings in ongoing educational programs.Conclusion:This study demonstrates the success of segmented online education in improving rheumatologists’ and pulmonologists’ knowledge and competence in evaluating risk and prognosis of fibrosing ILD and managing patients with CTD-ILDs. This could lead to earlier changes in therapeutic approach for those with signs of progression and result in improved overall outcomes for these patients.References:[1]Kolb M, Maher T, Smith V, Jacob J, Rimekasten G. Catching and Managing Progressive Fibrosing Interstitial Lung Disease Progression Earlier. Launched: Oct 9, 2020. Data as of Dec 18, 2020. Available at www.medscape.org/viewarticle/938826Disclosure of Interests:Christy Rohani-Montez: None declared, Marinella Calle: None declared, Chris Allen: None declared, Toby Maher Speakers bureau: Astra Zeneca, Bayer, Blade Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos, Galecto, GlaxoSmithKline R&D, Indalo, IQVIA, Pliant, Respivant, Roche and Theravance, Consultant of: Astra Zeneca, Bayer, Blade Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos, Galecto, GlaxoSmithKline R&D, Indalo, IQVIA, Pliant, Respivant, Roche and Theravance, Grant/research support from: Astra Zeneca and GlaxoSmithKline R&D, Vanessa Smith Speakers bureau: Boehringer-Ingelheim Pharma GmbH&Co and Janssen-Cilag NV, Consultant of: Boehringer-Ingelheim Pharma GmbH&Co, Grant/research support from: Research Foundation - Flanders (FWO), Belgian Fund for Scientific Research in Rheumatic diseases (FWRO), Boehringer-Ingelheim, Pharma GmbH&Co, and Janssen-Cilag NV, Joseph Jacob Speakers bureau: Boehringer-Ingelheim; Roche, Consultant of: Boehringer-Ingelheim, Grant/research support from: GlaxoSmithKline, Gabriela Riemekasten Speakers bureau: AbbVie; Actelion; Boehringer-Ingelheim, Consultant of: Actelion; CellTrend; Janssen, Grant/research support from: AbbVie; Actelion, Martin Kolb Speakers bureau: AstraZeneca; Boehringer-Ingelheim; Novartis; Roche, Consultant of: AbbVie Inc.; Algernon Pharma; AstraZeneca;, Boehringer-Ingelheim; Cipla; Covance; EPG Health; Galapagos NV; Gilead; GlaxoSmithKline; Indalo; MitoImmune Therapeutics Inc; Novartis; Pieris; Prometic (now Liminal Biosciences); Roche; Third Pole Inc.; TwoXAR Inc., Grant/research support from: Boehringer-Ingelheim; GlaxoSmithKline; Novartis; Prometic; Roche; Avalyn

scholarly journals AB0849 ONLINE EDUCATION YIELDS SIGNIFICANT GAINS IN RHEUMATOLOGISTS’ KNOWLEDGE OF PSORIATIC DISEASE

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1448.2-1449
Author(s):  
A. Stan ◽  
M. Calle ◽  
P. Schoonheim ◽  
A. B. Gottlieb
Keyword(s):  
Online Education ◽  
Correct Answer ◽  
P Value ◽  
Chi Square ◽  
Significance Level ◽  
Aggregated Data ◽  
Average Percentage ◽  
Psoriatic Disease ◽  
First Line Therapy ◽  
Post Assessment

Background:Physicians face challenges staying up-to-date with the latest research and accessing the ever-growing field of knowledge is time-consuming. Online education can make these clinician’s tasks more efficient and less time-consuming.Objectives:As part of a larger curriculum, we developed an online CME activity titled: “Optimizing Treatment in Patients With Moderate to Severe Psoriasis”. The goal of this study was to assess whether this online CME accredited video discussion improves physicians’ understanding of the prevalence and impact of the various manifestations of psoriatic disease, and how these might impact the choice of treatment in patients with psoriasis and/or psoriatic arthritis.Methods:Rheumatologists participated in an online CME activity (https://www.medscape.org/viewarticle/931595) consisting of a 30-minute video discussion between 2 experts with synchronized slides. Educational effect was assessed using a 4-question repeated pairs, pre-/post-assessment. A chi-square test determined if a statistically significant improvement (P <.05 significance level) existed in the number of correct responses from the pretest and posttest scores. Cramer’s V was used to estimate the level of impact of the education (Modest [.0]; Extensive [>.26]). The CME activity launched on Jul 6, 2020, and the data were collected through Aug 31, 2020.Results:A total of 54 rheumatologists completed the pre- and post activity assessments during the study period. Overall the activity had a signficiant impact (P =.0002) on rheumatologists’ knowledge and competence related to optimisation of treatment in psoriatic disease, with a Cramer’s V value of 0.210 indicating a considerable educational impact. The average percentage of correct responses rose from 67% pre-activity to 85% post-activity. A repeated pairs analysis showed that 21% of rheumatologists improved their knowledge and 64% reinforced their knowledge, respectively. The changes in percentage of correct responses from pre- to post-assessment for all questions are shown in Table 1. More than 60% of rheumatologists had a measurable improvement in confidence in their ability to identify patients with psoriatic disease who are candidates for first-line therapy with biologics.Table 1.Impact of education on rheumatologists’ knowledge of psoriatic diseaseQuestion #Question topicAggregated dataLinked Learner ResultsaAverage % of correct responses Pre- vs. Post-educationP-value% ImprovedblearnersPre- vs. Post-education% Reinforcedc learnersPre- vs. Post-education1.Prevalence of the various manifestations of psoriatic disease46% vs 80%.000235%44%2.Clinical data with biologic therapies in psoriatic disease69% vs 78%NS17%61%3.Competence related to identification of patients who may benefit from biologic therapy87% vs 98%.02711%87%aEach individual learner tracked pre and post-educationbIncorrect answer pre-education, Correct answer post-educationcCorrect answer pre-education, Correct answer post-educationConclusion:This online CME activity significantly improved rheumatologists’ knowledge and competence related to the optimization of treatment in psoriatic disease. However, there is room for further improving physicians’ knowledge of clinical trial outcomes with biologics in patients with PsA, since 22% of rheumatologists provided incorrect answers to question 3 post-education. This topic can be addressed in future educational programs.Disclosure of Interests:None declared

scholarly journals P579 Online Education Significantly Improved Gastroenterologists’ Knowledge of Treatment Options and Therapeutic Goals in Ulcerative Colitis

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S534-S535
Author(s):  
E Bell ◽  
M Calle ◽  
S Vermeire
Keyword(s):  
Ulcerative Colitis ◽  
Online Education ◽  
Clinical Data ◽  
Treatment Options ◽  
Further Education ◽  
Roundtable Discussion ◽  
Online Activity ◽  
Significance Level ◽  
Therapeutic Goals ◽  
Average Percentage

Abstract Background With the rapid evolution in treatment strategies and the increasing range of available therapeutics for ulcerative colitis (UC), keeping pace with advances can be a challenge for busy physicians. We assessed whether online CME can improve gastroenterologists’ knowledge of therapeutic goals and treatment options in UC. Methods Gastroenterologists participated in an online CME activity entitled ‘Management of UC: Expert Insights on Current and Emerging Therapies’. This was a 30-minute video roundtable discussion with accompanying slides. Educational effect was assessed using a repeated-pair design, pre-/post-assessment. A Chi-square test of independence determined if a statistically significant improvement (5% significance level, P&lt;.05) existed in the number of correct responses between the pre-test and post-test scores. Cramer’s V estimated the effect size of the education (&lt;.06, modest impact; .06-.15, noticeable impact; .16-.26, considerable impact; &gt;.26, extensive impact). The activity launched on 21 November 2019 with data collection through 4 February 2020. Results • Significant improvement in average percentage of correct responses, rising from 67% at baseline to 77% post-activity (P&lt;.001) and noticeable educational impact (Cramer’s V=0.113) • The percentage of gastroenterologists (n=232) answering all 3 questions correctly rose from 32% at baseline to 55% post-activity • Significant improvements in knowledge of the minimum therapeutic goal for a patient with moderate-to-severe UC (P&lt;.01) and the VTE risk associated with treatments for UC (P&lt;.01) • Numerical improvement in knowledge of clinical data from the UNIFI trial for ustekinumab in moderate-to-severe UC • Almost half (44%) of gastroenterologists indicated improved confidence in their ability to describe clinical data for emerging biologic agents in UC Conclusion Online education, delivered as a 30-minute video roundtable discussion among experts, significantly improved gastroenterologists’ knowledge of therapeutic goals and treatment options in UC, which should equip them with the knowledge to make more informed choices for their patients. The success of this online activity, particularly with regard to the impressive improvement in confidence, suggests that gastroenterologists would benefit from further education to reinforce not just their knowledge of clinical data for novel agents but also their confidence in using these new agents to manage patients with UC.

scholarly journals Small Steps, Big Gains: Impact of Health Promotion in Combating Viral Hepatitis

2021 ◽  
pp. 12-20
Author(s):  
Pranav Keshan ◽  
Archita Chaudhary ◽  
Aayushi Rastogi ◽  
Sapna Chauhan ◽  
Sabin Syed ◽  
...  
Keyword(s):  
Health Promotion ◽  
Viral Hepatitis ◽  
Medical Training ◽  
Statistical Significance ◽  
Training Period ◽  
Knowledge Gain ◽  
Clinical Practices ◽  
Significance Level ◽  
Attitude And Practice ◽  
Nursing Professionals

Background: Medical training in health sector is primarily aimed at holistic development of healthcare workers with respect to change in knowledge, attitude and practice, but the majority of trainings merely evaluate the change in knowledge of the participants after attending the training program. Since knowledge gain is immediate whereas change in attitude and practice requires time. Thus, limited evidence is available with respect to the effect of training on attitude and practice over a period of time. Aim: To assess the effect of training on modification of attitude and medical practices among nursing professionals at least six months of post-training period. Methods and Material: A longitudinal study from January 18, 2018 to January 31, 2020 was undertaken among nursing professionals who have taken pre and post-test knowledge assessment and have completed six months of post training period. The link to 28-item questionnaire was shared thrice with the eligible participants. All analyses were performed using IBM SPSS Version 22. The statistical significance level considered as p <0.05. Results: A total of 623 responses were received, of which 534 were included in the final analysis. The median follow-up period for the included participants was 9.4 months (IQR: 8.9–10.3 months). Mean age of the participants was 31.99±7.03years and 68% were females. Approximately 75% agreed that there was a change in their clinical practices with respect to viral hepatitis and approximately 72% unvaccinated individuals got themselves vaccinated post training. Conclusion: Health promotion through trainings is a pragmatic approach towards combating diseases and achieving sustainable development goals.

scholarly journals THU0585 ONLINE EDUCATION YIELDS SIGNIFICANT GAINS IN RHEUMATOLOGISTS’ KNOWLEDGE OF THE JAK INHIBITORS MODE OF ACTION AND CLINICAL TRIAL DATA

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 534.2-534
Author(s):  
A. Stan ◽  
M. Calle ◽  
C. Scot-Smith ◽  
R. Van Vollenhoven
Keyword(s):  
Clinical Trial ◽  
Online Education ◽  
Clinical Trial Data ◽  
Trial Data ◽  
Janus Kinase ◽  
Jak Inhibitors ◽  
Research Support ◽  
Educational Grant ◽  
Trial Outcomes ◽  
Post Assessment

Background:Physicians face challenges staying up-to-date with the latest research and accessing the ever-growing field of knowledge is time-consuming. Online education can make these clinician’s tasks more efficient and less time-consuming.Objectives:This study assessed whether the online CME accredited round-table-discussion with title “Meet the JAKs: Understanding the Role of Janus Kinase Inhibition in RA” improves physicians’ understanding mechanism of action (MOA) of current and emerging Janus kinase (JAK) inhibitors and rationale for their development in rheumatoid arthritis (RA).Methods:Rheumatologists participated in an online CME activity (https://www.medscape.org/viewarticle/913625) consisting of a 30-minute video discussion between 2 experts with accompanying slides. Educational effect was assessed using a 4-question repeated pairs, pre-/post-assessment. A chi-square test was used to determine if a statistically significant improvement (P<.05 significance level) existed in the number of correct responses from the pretest and posttest scores. Cramer’s V was used to estimate the level of impact of the education. The CME activity launched on June 4, 2019, and the data were collected through September 3, 2019.Results:A total of 107 rheumatologists completed the pre- and post activity assessments. Overall the activity had a signficiant impact (P<.001) on rheumatologists’ knowledge of JAK inhibitors and relatedclinical trial data with a Cramer’s V value of 0.319 indicating an extensive educational impact. The average percentage of correct responses rose from 47% pre-activity to 78% post-activity. The repeated pairs analysis (each individual learner tracked pre- and post-education) showed that 34% of learners improved their knowledge and 44% reinforced their knowledge. The change in percentage of correct responses from pre- to post-assessment achieved statistical significance for all 3 questions presented: (1) understanding the MOA of JAK inhibitors vs biologics (64% at baseline rising to 82% post acivity;P<0.01), (2) understanding the specificity of different JAK inhibitors (49% at baseline rising to 85% post acivity;P<.001), (3) knowledge of clinical trial outcomes with JAK inhibitors (29% at baseline rising to 67% post acivity;P<.001) and (4) 60% of rheumatologists gained confidence in their ability to describe the MOA of current and emerging JAK inhibitors.Conclusion:This online CME activity significantly improved rheumatologists’ understanding of JAK inhibitors mode of action. However, there is clearly room for further improving physicians’ knowledge of clinical trial outcomes with these agents, since one third of rheumatologists provided incorrect answers to question 3 post-activity) and this topic can be further addressed in future education.Acknowledgments:This CME-certified activity was supported by anindependent educational grant from AbbVie.Disclosure of Interests:Adriana Stan Grant/research support from: The CME-certified activity was supported by anindependent educational grant from Sandoz., Marinella Calle Grant/research support from: This CME-certified activity was supported by anindependent educational grant from Novartis AG, Camille Scot-Smith Grant/research support from: This CME-certified activity was supported by anindependent educational grant from AbbVie, Ronald van Vollenhoven Grant/research support from: BMS, GSK, Lilly, UCB, Pfizer, Roche, Consultant of: AbbVie, AstraZeneca, Biogen, Biotest, Celgene, Gilead, Janssen, Pfizer, Servier, UCB, Speakers bureau: AbbVie, Pfizer, UCB

scholarly journals THU0651-HPR ONLINE EDUCATION YIELDS SIGNIFICANT GAINS IN RHEUMATOLOGISTS’ KNOWLEDGE OF THE ROLE OF ENTHESITIS IN THE DIAGNOSIS AND MANAGEMENT OF PSA

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 570.1-570
Author(s):  
A. Stan ◽  
M. Calle ◽  
P. Schoonheim ◽  
P. J. Mease
Keyword(s):  
Clinical Trial ◽  
Psoriatic Arthritis ◽  
Online Education ◽  
Correct Answer ◽  
Research Support ◽  
Diagnosis And Management ◽  
Educational Grant ◽  
Trial Outcomes ◽  
Post Assessment

Background:Physicians face challenges staying up-to-date with the latest research and accessing the ever-growing field of knowledge is time-consuming. Online education can make these clinician’s tasks more efficient and less time-consuming.Objectives:As part of a larger curriculum, we developed an online CME activity titled: “Enthesitis in Psoriatic Arthritis: Disease, Diagnosis and Decisions”. The goal of this study was to assess whether this online CME accredited video discussion improves physicians’ understanding of the role of enthesitis in the diagnosis and management of patients with psoriatic arthritis (PsA) in clinical practice.Methods:Rheumatologists participated in an online CME activity (https://www.medscape.org/viewarticle/910671) consisting of a 30-minute video discussion between 2 experts with accompanying slides. Educational effect was assessed using a 4-question repeated pairs, pre-/post-assessment. A chi-square test was used to determine if a statistically significant improvement (P<.05 significance level) existed in the number of correct responses from the pretest and posttest scores. Cramer’s V was used to estimate the level of impact of the education. The CME activity launched on March 28, 2019, and the data were collected through June 7, 2019.Results:A total of 145 rheumatologists completed the pre- and post activity assessments. Overall the activity had a signficiant impact (P<.0001) on rheumatologists’ knowledge of the role of enthesitis in the diagnosis and management of PsA, with a Cramer’s V value of 0.153 indicating a noticeble educational impact. The average percentage of correct responses rose from 54% pre-activity to 69% post-activity. A repeated pairs analysis showed that 22% of rheumatologists improved their knowledge and 47% reinforced their knowledge, respectively. The change in percentage of correct responses from pre- to post-assessment for all questions are shown in table. Almost 40% of rheumatologists had a measurable improvement in confidence in their ability to evaluate the presence of enthesitis according to a clinical exam or ultrasound.Table.Impact of education on rheumatologists’ knowledge of enthesitisQuestion #Question topicAggregated dataLinked Learner ResultsaAverage % of correct responses Pre- vs. Post-educationP-value% ImprovedblearnersPre- vs. Post-education% ReinforcedclearnersPre- vs. Post-education1.Immunopathology of PsA75% vs 84%.057912%72%2.Prevalence of enthesitis in patients with PsA44% vs 68%<.000133%34%3.Clinical trial outcomes in patients with enthesitis43% vs 56%.034522%34%aEach individual learner tracked pre and post-educationbIncorrect answer pre-education, Correct answer post-educationcCorrect answer pre-education, Correct answer post-educationConclusion:This online CME activity significantly improved rheumatologists’ understanding of role of enthesitis in the diagnosis and management of PsA. However, there is clearly room for further improving physicians’ knowledge of clinical trial outcomes with biologics in patients with enthesitis, since 44% of rheumatologists provided incorrect answers to question 3 post-education. This topic can be addressed in future education.Acknowledgments:This CME-certified activity was supported by independent funding from Novartis AG.Disclosure of Interests:Adriana Stan Grant/research support from: The CME-certified activity was supported by an independent educational grant from Sandoz., Marinella Calle Grant/research support from: This CME-certified activity was supported by an independent educational grant from Novartis AG, Peter Schoonheim Grant/research support from: This CME-certified activity was supported by independent funding from Sandoz., Philip J Mease Grant/research support from: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – grant/research support, Consultant of: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – consultant, Speakers bureau: Abbott, Amgen, Biogen Idec, BMS, Eli Lilly, Genentech, Janssen, Pfizer, UCB – speakers bureau

Sign in / Sign up

Export Citation Format

Share Document